BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES

Size: px
Start display at page:

Download "BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES"

Transcription

1 BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies. Our Pharmacy and Therapeutics (P&T) Committee is made up of a group of practicing physicians and pharmacists who meet quarterly to recommend changes to our formulary based on the latest medical literature, new clinical guidelines, new information from key physician experts, and new information from the Food and Drug Administration. Changes to the Standard Drug Formulary from the P&T Committee meeting are outlined below. To view a copy of the Standard Drug Formulary, please download a copy. The drugs listed below are to be used for FDA-approved indications but may also be used for other conditions. 1. DRUGS ADDED TO FORMULARY The following drugs were added to the formulary: Drug FDA Indication(s) Coverage Restriction(s) Tier Status cyclopentolate 2% drops (generic Cyclogyl) fluticasone propionate (generic Flonase) metformin extendedrelease tablet (generic Glumetza) naftifine 2% cream (generic Naftin) naloxone 0.4mg/ml vial and syringe, 2mg/2ml syringe norgestimate-ethinyl estradiol, tri-lo-sprintec, tri-lo-estarylla, trinessa lo, tri-lo-marzia (generic Ortho Tri-Cyclen Lo) olopatadine 0.1% drops (generic Patanol) Otezla Praluent pramipexole 2.25mg extended-release (generic Mirapex ER) Tanzeum Mydriasis, Cycloplegia Allergic and non-allergic rhinitis Tinea pedis, Tinea cruris, Tinea corporis Prior authorization required. Step therapy required Opioid overdose Add quantity limit Prevent pregnancy Allergic conjunctivitis Psoriatic arthritis, Plaque psoriasis Hypercholesterolemia Prior authorization required, Prior authorization required, Tier 4 # Tier 4 # Parkinson s disease Step therapy required, Page 1 of 6

2 Drug FDA Indication(s) Coverage Restriction(s) Tier Status Toujeo Solostar Diabetes # must be obtained through a network specialty pharmacy Tier 2 (effective 1/1/2017) 2. FORMULARY DRUGS WITH CHANGES TO TIER AND/OR COVERAGE RESTRICTION The following drugs have coverage restriction(s) added or removed, and/or change of tier status as noted: DRUG FDA Indication(s) Coverage Restriction(s) Tier Status aripiprazole (generic Abilify) tablet, solution mania, Depression, Autistic, Tourette s Add quantity limit Azilect Parkinson s disease budesonide (generic Entocort EC) clobetasol (generic Clobex) lotion clobetasol (generic Clobex) shampoo Crohn s disease Corticosteroid responsive, Plaque psoriasis, quantity limit (effective 2017) Step therapy required Tier 2 Scalp psoriasis Step therapy required clozapine odt (generic Fazaclo) Schizophrenia dihydroergotamine mesylate (generic D.H.E. 45) dihydroergotamine (generic Migranal) nasal Epivir HBV solution exemestane (generic Aromasin) fluocinolone (generic Synalar) solution lamivudine (generic Epivir HBV) tablet metformin extended-release (generic Fortamet) phenoxybenzamine (generic Dibenzyline) Migraine, Cluster headache Migraine Hepatitis B Breast cancer Corticosteroid responsive Hepatitis B Pheochromocytoma Prior authorization required. Add step therapy.. Remove prior authorization. Remove age and gender edit Add step therapy. Remove prior authorization Tier 4 Tier 4 Tier 2 Page 2 of 6

3 risperidone odt (generic Risperdal M-Tab) ziprasidone (generic Geodon) Anti-retrovirals abacavir (generic Ziagen) tablet abacavir/lamivudine/zidovudine (generic Trizivir), Autistic HIV infection Add quantity limit HIV infection Add quantity limit Atripla HIV infection Add quantity limit Complera HIV infection Add quantity limit Crixivan HIV infection Add quantity limit Tier 2 didanosine (generic Videx EC) HIV infection Add quantity limit Edurant HIV infection Add quantity limit Tier 2 Emtriva HIV infection Add quantity limit Tier 2 Epzicom HIV infection Add quantity limit Tier 2 Intelence HIV infection Step therapy required. Add quantity limit Tier 2 Invirase HIV infection Add quantity limit Tier 2 Isentress HIV infection Add quantity limit Tier 2 Kaletra HIV infection Add quantity limit Tier 2 lamivudine (generic Epivir) HIV infection Add quantity limit lamivudine/zidovudine (generic Combivir) HIV infection Add quantity limit Lexiva HIV infection Add quantity limit Tier 2 nevirapine (generic Viramune) HIV infection Add quantity limit nevirapine extende-release (generic Viramune R) HIV infection Add quantity limit Norvir HIV infection Add quantity limit Tier 2 Prezista HIV infection Add quantity limit Tier 2 Rescriptor HIV infection Add quantity limit Tier 2 Reyataz capsule HIV infection Add quantity limit Tier 2 Selzentry HIV infection Prior authorization required. Add quantity limit Tier 2 stavudine (generic Zerit) HIV infection Add quantity limit Sustiva HIV infection Add quantity limit Tier 2 Truvada HIV infection Add quantity limit Tier 2 Page 3 of 6

4 Viracept HIV infection Add quantity limit Tier 2 zidovudine (generic Retrovir) capsule, syrup HIV infection Add quantity limit 3. DRUGS REMOVED FROM THE FORMULARY The following drugs will be removed from the formulary starting January Non-formulary drugs require a formulary exception based on medical necessity for coverage. Drug FDA Indication(s) Formulary Alternative(s) Bydureon, Bydureon pen, Byetta metformin, sulfonylurea, TZD, Tanzeum (steptherapy required) Glucophage metformin (generic Glucophage) Glucophage XR metformin extended release (generic Glucophage XR) Glucovance glyburide/metformin (generic Glucovance) Kasano, Nesina, Oseni Kombiglyze XR, Onglyza Latuda Januvia, Janumet (step therapy required for both) Januvia, Janumet (step therapy required for both) olanzapine, quetiapine, risperidone Levemir, Levemir Flextouch Diabetes Lantus, Toujeo metformin extended-release (generic Fortamet) metformin extended-release (generic Glucophage XR) Nasonex Allergic rhinitis fluticasone nasal Nuvigil olanzapine-fluoxetine (generic Symbyax) Saizen Saphris Seroquel XR Topical Corticosteroids Obstructive sleep apnea, Narcolepsy, Shift work Bipolar, Depression Growth hormone deficiency mania, Depression modafinil (PA required) olanzapine, quetiapine, risperidone Nutropin, Nutropin AQ (PA required) olanzapine, quetiapine, risperidone quetiapine (generic Seroquel) Page 4 of 6

5 Drug FDA Indication(s) Formulary Alternative(s) amcinonide cream, lotion, ApexiCon E betamethasone valerate (generic Luxiq) foam clobetasol (generic Clobex) spray Clodan clocortolone (generic Cloderm) cream desonide (generic Desowen) lotion desoximetasone (generic Topicort) 0.05% cream desoximetasone (generic Topicort) gel,, 0.25% cream diflorasone cream, fluocinolone (generic Derma- Smoothe-FS) body oil fluocinolone (generic Derma- Smoothe-FS) scalp oil fluticasone (generic Cutivate) lotion of the scalp Plaque psoriasis Scalp psoriasis Atopic dermatitis Scalp psoriasis fluocinonide 0.05% gel, cream,, solution; betamethasone augmented 0.05% cream, lotion,, gel fluocinonide 0.05% gel, cream,, solution; betamethasone augmented 0.05% cream, lotion,, gel, lotion; betamethasone valerate 0.1% cream,, lotion; TAC 0.1% cream,, lotion; fluticasone 0.05% cream, ; mometasone 0.1% cream, clobetasol cream,, solution, gel, cream emollient clobetasol cream,, solution, gel, cream emollient, lotion; betamethasone valerate 0.1% cream,, lotion; TAC 0.1% cream,, lotion; fluticasone 0.05% cream, ; mometasone 0.1% cream, hydrocortisone 2.5% cream,, lotion; alclometasone 0.05% cream,, lotion; betamethasone valerate 0.1% cream,, lotion; TAC 0.1% cream,, lotion; fluticasone 0.05% cream, ; mometasone 0.1% cream, fluocinonide 0.05% gel, cream,, solution; betamethasone augmented 0.05% cream, lotion,, gel betamethasone, augmented 0.05% lotion,, gel, cream hydrocortisone 2.5% cream,, lotion; alclometasone 0.05% cream, hydrocortisone 2.5% cream,, lotion; alclometasone 0.05% cream,, lotion; betamethasone valerate 0.1% cream,, lotion; TAC 0.1% cream,, lotion; fluticasone 0.05% cream, ; mometasone 0.1% cream, Page 5 of 6

6 Drug FDA Indication(s) Formulary Alternative(s) hydrocortisone butyrate/emollient (generic Locoid Lipocream) cream Scalacort triamcinolone acetonide (generic Kenalog) spray Trianex, lotion; betamethasone valerate 0.1% cream,, lotion; TAC 0.1% cream,, lotion; fluticasone 0.05% cream, ; mometasone 0.1% cream, hydrocortisone 2.5% cream,, lotion; alclometasone 0.05% cream,, lotion; betamethasone valerate 0.1% cream,, lotion; TAC 0.1% cream,, lotion; fluticasone 0.05% cream, ; mometasone 0.1% cream,, lotion; betamethasone valerate 0.1% cream,, lotion; TAC 0.1% cream,, lotion; fluticasone 0.05% cream, ; mometasone 0.1% cream, 4. DRUGS REMOVED FROM COVERAGE The following drugs were excluded from coverage because they are not approved by the Food and Drug Administration (FDA): Drug Ala-quin cream hydrocortisone-iodoquinol cream, cream pack Iodosorb gel Drug Nicomide Ultrasal ER Vytone Page 6 of 6

Step Therapy Criteria 2019

Step Therapy Criteria 2019 Step Therapy 2019 For information on obtaining an updated coverage determination or an exception to a coverage determination please call Freedom Health Member Services at 1-800-401-2740 or, for TTY/TDD

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Provider Bulletin June 2017 The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. These changes were reviewed and approved at the first quarter Pharmacy and Therapeutics

More information

May 2016 P & T Updates

May 2016 P & T Updates Commercial Triple Tier 4th Tier Applicabl e Traditional Detailed s 2 films - DESCOVY 2 2 1 tablet NARCAN 2 2 ODEFSEY 2 2 1 tablet REPATHA 2 2 HoFH: 3 ml per 28 ROSUVASTATIN 1 1 - UPTRAVI 3 2 - Alternatives

More information

Topical Immunomodulators

Topical Immunomodulators Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Topical Immunomodulators Clinical Edit Information Included in this Document Topical Immunomodulators Elidel and Protopic 0.03%

More information

Quarterly Pharmacy Formulary Change Notice

Quarterly Pharmacy Formulary Change Notice MEDICAID PROVIDER BULLETIN February 26, 2015 Quarterly Pharmacy Formulary Change Notice Summary of Change: The formulary changes listed in the table below were reviewed and approved at our September 24,

More information

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

2015 Step Therapy Prior Authorization Medical Necessity Guidelines Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154

More information

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018 Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017

More information

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION A1. PARTICIPANT ID: ENTER NUMBER HERE - - - ONLY IF ID LABEL IS NOT AVAILABLE A2. VISIT #: A3. VERSION DATE: 1 0 /

More information

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/

More information

The Medical Letter. on Drugs and Therapeutics

The Medical Letter. on Drugs and Therapeutics The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

Effective for all members on August 1, 2017

Effective for all members on August 1, 2017 August 2017 Pharmacy Formulary Change Notice BlueChoice HealthPlan Medicaid is here to help you stay on top of your health care. We want to tell you about some upcoming changes to your Preferred Drug List

More information

Comparison of representative topical corticosteroid preparations (classified according to the US system)

Comparison of representative topical corticosteroid preparations (classified according to the US system) Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),

More information

2017 Formulary Changes Year to Date

2017 Formulary Changes Year to Date 2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or

More information

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM ID LABEL HERE ---> VERSION DATE 10/01/07 - - - VISIT #: FORM COMPLETED BY: A1. DATE OF BLOOD DRAW: / / M D Y A2. Do you take

More information

HIV Drugs and the HIV Lifecycle

HIV Drugs and the HIV Lifecycle HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's

More information

Step Therapy Requirements

Step Therapy Requirements An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 12/01/2017 Updated 11/2017 H0302_2_2014 CMS Accepted 05/05/2014 1 ABILIFY Abilify 10 mg tablet

More information

Emblem Medicaid 4th Quarter Formulary Updates

Emblem Medicaid 4th Quarter Formulary Updates abacavir 20 mg/ml solution Added to Formulary (generic) with Quantity Limits 12/1/2017 abacavir 300 mg tablet Added Quantity Limits 10/1/2017 abacavir-lamivudine 600-300 mg Added Quantity Limits 10/1/2017

More information

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work THE HIV LIFE CYCLE Understanding How Antiretroviral Medications Work DEFINITIONS Host: The animal or cell that another organism lives in. In HIV human CD4 T-cells are the host for HIV. Nucleus: The core

More information

Eucrisa. Eucrisa (crisaborole) Description

Eucrisa. Eucrisa (crisaborole) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa

More information

2018 Step Therapy (ST) Criteria

2018 Step Therapy (ST) Criteria 2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a

More information

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs

More information

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs

More information

Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan

Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Agenda: Introductions Approval of Minutes of July 8, 2014 Meeting P & T Business Review

More information

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE: FUZEON (enfuvirtide) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs

More information

Appropriate Use & Safety Edits

Appropriate Use & Safety Edits Appropriate Use & Safety Edits Envolve Pharmacy Solutions provides a variety of safety edits to promote the use of the right medication, in the right patient, at the right time. These edits are routinely

More information

Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 2011

Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 2011 Beneficiary Advisory Panel Handout Uniform Formulary Decisions 23 June 211 PURPOSE: The purpose of this handout is to provide BAP Committee members with a reference document for the relative clinical effectiveness

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017

More information

Eucrisa. Eucrisa (crisaborole) Description

Eucrisa. Eucrisa (crisaborole) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)

More information

Step Therapy Requirements

Step Therapy Requirements An Independent Licensee of the Blue Cross and Blue Shield Association Step Therapy Requirements Effective: 05/01/2018 Updated 4/2018 H0302_2_2014 CMS Accepted 05/05/2014 1 BETA-BLOCKERS BYSTOLIC 10 MG

More information

The safety and effectiveness of Dupixent in pediatric patients have not been established (1).

The safety and effectiveness of Dupixent in pediatric patients have not been established (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent

More information

Antiretrovial Crushable/Liquid Formulation Chart

Antiretrovial Crushable/Liquid Formulation Chart Antiretrovial Crushable/Liquid Formulation Chart Eliza Dollard, PharmD; Nafeesa Chin-Beckford, PharmD; Laura Aragon, PharmD Last Updated: 04/2016 Agent How Supplied Crushable Status **Products listed in

More information

HIV medications HIV medication and schedule plan

HIV medications HIV medication and schedule plan Living with HIV (human immunodeficiency virus) It may be scary to find out that you re HIV-positive or have AIDS. Coping with this news may be difficult. Although HIV is a serious infection, people with

More information

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir

More information

Drug Class Literature Scan: Topical Steroids

Drug Class Literature Scan: Topical Steroids Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS - 2014 Alabama s ADAP formulary offers a minimum of one medication from each HIV antiretroviral class approved by the U.S. Food and Drug Administration (FDA).

More information

TEST ANTICONVULSANT THERAPY. Products Affected. Step 2: Network Health Insurance Corporation NetworkCares Step Therapy Criteria Last Updated 11/2018

TEST ANTICONVULSANT THERAPY. Products Affected. Step 2: Network Health Insurance Corporation NetworkCares Step Therapy Criteria Last Updated 11/2018 TEST Network Health Insurance Corporation NetworkCares Step Therapy Last Updated 11/2018 ANTICONVULSANT THERAPY Aptiom Banzel Briviact Celontin Dilantin 30 Mg Capsule Equetro Fycompa 0.5 Mg/ml Oral Susp

More information

Topical Immunomodulators

Topical Immunomodulators Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Topical Immunomodulators Clinical Criteria Information Included in this Document Topical Immunomodulators Elidel and Protopic 0.03% Drugs

More information

Prior Authorization Topical Immunomodulators Elidel and Protopic 0.03%

Prior Authorization Topical Immunomodulators Elidel and Protopic 0.03% Drugs Requiring Label Name GCN ELIDEL 1% CREAM 15348 PROTOPIC 0.03% OINTMENT 12289 TACROLIMUS 0.03% OINTMENT 12289 Clinical Edit Criteria Logic 1. Does the client have a diagnosis of localized skin graft

More information

Update to HMO Drug Formulary Tier Definitions. February 8, 2018

Update to HMO Drug Formulary Tier Definitions. February 8, 2018 Update to HMO Drug Formulary Tier Definitions February 8, 2018 Agenda 1 Overview of Current Drug Tiers 2 Proposed Drug Tiers for 2019 3 Impact to SFHSS and SFHSS Members 4 How the Drug Formulary Works

More information

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care www.nwaetc.org The Northwest AIDS Education and Training Center (NW AETC), located at the University

More information

Comparison of representative topical corticosteroid preparations (classified according to the US system)

Comparison of representative topical corticosteroid preparations (classified according to the US system) Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),

More information

Page 1 of 5 ENLGLISH / ESPAÑOL / PORTUGUÉS / FRANÇAIS Share 3 Drug Chart for HIV Treatment CURRENT EDITION ABOUT SENSE BACK ISSUES MSMGF HOME CONTACT US There are a number of antiretroviral (ARV) medications

More information

BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES

BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.

More information

Midwestern Underwriting Conference 2016

Midwestern Underwriting Conference 2016 UNDERWRITING HIV: THE FAIRY TALE HAS BECOME REALITY Midwestern Underwriting Conference 2016 Jean-Marc Fix, FSA, MAAA VP, R&D, Optimum Re Insurance Co. AGENDA Where are we with HIV? The risk The ideal case

More information

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options STRATEGIES FOR THIRD LINE HIV THERAPY issues to consider when faced with few drug options A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Most people living

More information

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication. ADHD STIMULANTS ATOMOXETINE HCL, DEXEDRINE 10 MG TABLET, DEXEDRINE 5 MG TABLET, DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, DEXTROAMPHETAMINE 10 MG TAB, DEXTROAMPHETAMINE 5 MG TAB, DEXTROAMPHETAMINE

More information

ALLERGIC RHINITIS-NASAL

ALLERGIC RHINITIS-NASAL ALLERGIC RHINITIS-NASAL FLUNISOLIDE Patient needs to have paid claims for any one of the following Step 1 drugs: NasaCort OTC, fluticasone Rx, fluticasone OTC, Budesonide OTC. Prior to filling the Step

More information

FLORIDA!A MEDICAID' Better Health Care for all Floridians. May

FLORIDA!A MEDICAID' Better Health Care for all Floridians. May CHARLIE CRIST GOVERNOR FLORIDA!A MEDICAID' Better Health Care for all Floridians HOllY BENSON SECRETARY May 26. 2009 Policy Transmittal: HMO 09-01 Policy Transmittal: PS 09-01 RE: Year Thrcc PerFormance

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Enstilar, Sernivo, Taclonex) Reference Number: CP.CPA.255 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end

More information

OB/GYN CHART REVIEW DRAFT: NOT FOR DISTRTIBUTION

OB/GYN CHART REVIEW DRAFT: NOT FOR DISTRTIBUTION OB/GYN CHART REVIEW A summary of OB/GYN clinical chart review results designed to monitor the quality of care provided by a Ryan White funded OB/GYN primary care site as part of the Atlanta EMA s quality

More information

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920 0.14 UNAIDS 0.053% 2 250 60 10% 94 73 20 73-94/6 8,920 12 43 Public Health Service Task Force Recommendations 5-10% for Use of Antiretroviral Drugs in 10-20% Pregnant HIV-1-Infected Women for Maternal

More information

Rationale for Decision Excluded Generic OTC equivalent available (Flonase Allergy Relief) Medicare status (if differs)

Rationale for Decision Excluded Generic OTC equivalent available (Flonase Allergy Relief) Medicare status (if differs) BLUE SHIELD OF CALIFORNIA FIRST QUARTER 2015 FORMULARY AND MEDICATION POLICY UPDATES EFFECTIVE MARCH 19, 2015 The Blue Shield of California (BSC) Pharmacy and Therapeutics (P&T) Committee, consisting of

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

2018 CareOregon Advantage Part D Formulary Changes

2018 CareOregon Advantage Part D Formulary Changes 2018 CareOregon Advantage Part D Formulary Changes Abbreviations: AGE = Age Restriction; PA = Prior Authorization Required; QL = Quantity Limit; ST = Step Therapy Required; LD = Limited Distribution; BvD

More information

Antiretroviral Dosing in Renal Impairment

Antiretroviral Dosing in Renal Impairment Protease Inhibitors (PIs) Atazanavir Reyataz hard capsules 300 mg once daily taken with ritonavir 100 mg once daily No dosage adjustment is needed for atazanavir in renal impairment Atazanavir use in haemodialysis

More information

Pharmacy Benefit Determination Policy

Pharmacy Benefit Determination Policy Policy Subject: Atopic Dermatitis Agents Policy Number: SHS PBD18 Category: Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual HMO/POS PPO ASO s:

More information

Genotyping and Drug Resistance in Clinical Practice. Case Studies

Genotyping and Drug Resistance in Clinical Practice. Case Studies Genotyping and Drug Resistance in Clinical Practice Case Studies 12/02 40 year old Hispanic male Dx with HIV 1995 + Hx of PCP > 1x, HepC Medication history: AZT, Crixivan, Videx EC, Sustiva, Zerit, Ziagen,

More information

Dupixent (dupilumab)

Dupixent (dupilumab) Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

Antipsychotic Medications Age and Step Therapy

Antipsychotic Medications Age and Step Therapy Market DC *- Florida Healthy Kids Antipsychotic Medications Age and Step Therapy Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Virginia Medicaid See State Specific Mandates *Indiana

More information

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection Table 3. Characteristics of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Generic Name (Abbreviation) / Trade Name Abacavir (ABC) / Ziagen Trizivir with ZDV + 3TC Epzicom with 3TC Didanosine (ddi)

More information

HIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time

HIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time STRATEGIES FOR FIRST LINE HIV THERAPY issues to think about when going on therapy for the first time A PUBLICATION FROM Information, Inspiration and Advocacy for People Living With HIV/AIDS MAY 2008 Deciding

More information

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review

More information

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates

Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates April 2018 TRADE NAME (generic name) or generic name Brand/Generic Description of Change abacavir sulfate soln 20 mg/ml (base equiv) Generic

More information

Drug Formulary Update, July 2016 Commercial and State Programs

Drug Formulary Update, July 2016 Commercial and State Programs Drug Formulary Update, July 2016 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,

More information

ANTICONVULSANT THERAPY

ANTICONVULSANT THERAPY Network Health Insurance Corporation NetworkCares Step Therapy Last Updated: 7/2017 ANTICONVULSANT THERAPY Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200

More information

Children s Hospital Of Wisconsin

Children s Hospital Of Wisconsin Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,

More information

Step Therapy Requirements. Effective: 12/01/2016

Step Therapy Requirements. Effective: 12/01/2016 Effective: 12/01/2016 H2986_PD_049 Updated 11/2016 ALPHA 1-PROTEINASE INHIBITOR GLASSIA PRIOR CLAIM FOR ARALAST NP OR ZEMAIRA WITHIN THE PAST 120 DAYS. ANALGESICS, NARCOTICS KADIAN MORPHINE SULFATE ER

More information

FirstCarolinaCare Insurance Company Step Therapy Requirements

FirstCarolinaCare Insurance Company Step Therapy Requirements ANALGESICS, NARCOTICS KADIAN MORPHINE SULFATE ER PRIOR CLAIM FOR MORPHINE SULFATE SUSTAINED ACTION TABLET (MS CONTIN) WITHIN THE PAST 120 DAYS. ANTIBACTERIALS (EENT) BESIVANCE PRIOR CLAIM FOR CIPROFLOXACIN

More information

ANTIRETROVIRAL TREATMENTS (Part 1of

ANTIRETROVIRAL TREATMENTS (Part 1of CCR5 CO-RECEPTOR ANTAGONISTS maraviroc (MVC) Selzentry 25mg, 75mg, FUSION INHIBITORS 20mg/mL ANTIRETROVIRAL TREATMENTS (Part 1of 5) oral soln enfuvirtide (ENF, T-20) Fuzeon 90mg/mL pwd for SC inj after

More information

PPHP 2017 Formulary 2017 Step Therapy Criteria

PPHP 2017 Formulary 2017 Step Therapy Criteria ARISTADA Aristada Prefilled Syringe 1064 MG/3.9ML Intramuscular Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882

More information

HIV and YOU. Special 2008 Update!

HIV and YOU. Special 2008 Update! HIV and YOU Special 2008 Update! HIV and You Special 2008 Update! In this booklet, you ll see words in bold, red type. Go to the Glossary on the back cover to find out what these words mean. WRITERS AND

More information

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL Generic Name COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir)

More information

2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview

2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview 2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview In some cases, UCare requires you to first try certain drugs to treat your medical condition before

More information

Step Therapy Medications

Step Therapy Medications Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on

More information

HIV Infection & AIDS in Low- and Middle-Income Countries

HIV Infection & AIDS in Low- and Middle-Income Countries GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 25: HIV Infection & AIDS in Low- and Middle-Income Countries Author P. Van de Perre, MD, PhD Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues

More information

Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: February 20, 2017

Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: February 20, 2017 Pharmacy Medical Necessity Guidelines: Effective: February 20, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)

More information

AIDS Drug Assistance Program ADAP-Miami. NEEDS ASSESSMENT July 16, 2010

AIDS Drug Assistance Program ADAP-Miami. NEEDS ASSESSMENT July 16, 2010 AIDS Drug Assistance Program ADAP-Miami NEEDS ASSESSMENT July 16, 2010 ADAP Clients - Gender ADAP Clients by Gender FY 09/10 April 2010 to June 2010 26% 0% Males Females 26% 0% Males Females Transgender

More information

Pharmacologic Treatment of Atopic Dermatitis

Pharmacologic Treatment of Atopic Dermatitis J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc

More information

Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: December 12, 2017

Pharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: December 12, 2017 Pharmacy Medical Necessity Guidelines: Effective: December 12, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)

More information

Adherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA)

Adherence Strategies for Older Adults. AIDS Community Research Initiative of America (ACRIA) Adherence Strategies for Older Adults AIDS Community Research Initiative of America (ACRIA) June 2008 Modular Objectives By the end of the module, participants will be able to: Define adherence Be able

More information

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO Ont. Drug Distr. Ontario Drug Benefit/Trillium: Other Formulary (F/A) Limited Use (Section 16) Antiretrovirals AZT 100 mg capsules NRTIs (single): Abacavir,

More information

FORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary

FORMULARY Virginia (VA) AIDS Drug Assistance Program (ADAP) LAST UPDATED: December At a Glance: VA ADAP Formulary At a Glance: VA ADAP Formulary Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) Non Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Multi Class Combination Agents Protease Inhibitors

More information

LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION

LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION Added Prior Authorization 7/1/17 CORLANOR 5 MG TABLET Added Prior Authorization 7/1/17 CORLANOR 7.5 MG TABLET Added Prior Authorization 7/1/17

More information

Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)

Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) Diagnosis: ATOPIC DERMATITIS (AD) Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) PATIENT ADVICE: Unfortunately, there is no cure for atopic dermatitis, so

More information

Pharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS

Pharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS Workforce Safety & Insurance Revised Document Date: 07/21/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management

More information

BlueLink TPA FlexRx Updates

BlueLink TPA FlexRx Updates BlueLink TPA FlexRx Updates April 2018 TRADE NAME (generic name) or generic name abacavir sulfate soln 20 mg/ml (base equiv) Generic Addition, generic for ZIAGEN alclometasone dipropionate cream 0.05%

More information

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL

COMPREHENSIVE ANTIRETROVIRAL TABLE: ADULT DOSING**, DOSAGE FORM MODIFICATIONS, ADVERSE REACTIONS and INTERACTION POTENTIAL COMPREHENSIVE ANTIRETROVIRAL TABLE: NUCLOESIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (N(t)RTIs) Abacavir ABC (Ziagen) Didanosine ddi (Videx EC) Emtricitabine FTC (Emtriva) Lamivudine 3TC (Epivir) Stavudine

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 EDURANT 25 mg film-coated tablets B/30 (CIP code: 219 472-9) Applicant: JANSSEN-CILAG rilpivirine ATC code

More information

BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search

BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search Search 1 :When to Initiate ART Covers Questions 1-5 including to prevent transmission Component Description Review area Objectives

More information

ANTIDIABETIC AGENTS - MISCELLANEOUS

ANTIDIABETIC AGENTS - MISCELLANEOUS ANTIDIABETIC AGENTS - MISCELLANEOUS Glyxambi 10 mg-5 mg tablet Glyxambi 25 mg-5 mg tablet Invokamet 150 mg-1,000 mg tablet Invokamet 150 mg-500 mg tablet Invokamet 50 mg-1,000 mg tablet Invokamet 50 mg-500

More information

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date: Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications Carrie Allen PharmD, CGP, BCPS, BCPP, CCHP Overview - Part 2: HIV

More information

ADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute

ADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute ADAP Monitoring Provider Prescribing Patterns Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute WEBINAR ETIQUETTE All questions or comments can be shared either via the

More information

Blue Medicare HMO Essential 2015 Quantity Limit List Blue Medicare Rx Standard 2015 Quantity Limit List

Blue Medicare HMO Essential 2015 Quantity Limit List Blue Medicare Rx Standard 2015 Quantity Limit List Blue Medicare HMO Essential 2015 Quantity Limit List Blue Medicare Rx Standard 2015 Quantity Limit List Drug Name Monthly Limit (30 days unless otherwise noted) abacavir 300 mg abacavir/lamivudine/zidovudine

More information

TennCare Program TN MAC Price Change List As of: 03/30/2017

TennCare Program TN MAC Price Change List As of: 03/30/2017 1 TN List Run : 03/30/17 Old PRAZOSIN HCL 5 MG CAPSULE ORAL 03/29/2017 1.11209 1.12560 ( 1.2) CAPTOPRIL 12.5 MG TABLET ORAL 07/07/2015 1.07191 1.10416 ( 2.9) ISOSORBIDE DINITRATE 5 MG TABLET ORAL 03/29/2017

More information

ADHD STIMULANTS-S(SHC)

ADHD STIMULANTS-S(SHC) Step Therapy Simply Health Care 2014 Formulary ID: 14406 Version: 14 Last Updated: 08/01/2014 ADHD STIMULANTS-S(SHC) Daytrana Focalin Xr Strattera Patient needs to have a paid claim for one Step 1 drug

More information

UnitedHealthcare Community Plan PDL Modifications. Added as an alternative agent for the 9/1/ /1/2012

UnitedHealthcare Community Plan PDL Modifications. Added as an alternative agent for the 9/1/ /1/2012 Avonex Pen Interferon beta-1a Added as alternative dosing formulation for the treatment of multiple sclerosis. Prior Korlym Mifepristone Added as alternative agent to control hyperglycemia secondary to

More information